Boardroom Alpha
Boardroom Alpha
ASTH · Additional Proxy Materials (DEFA14A) · Filed April 17, 2026

Astrana Health Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 17, 2026
Ticker
ASTH
Accession
0001104659-26-044544
Boardroom Alpha · Filing insights

Astrana Health's board recommends voting for all four proposals at the 2026 annual meeting. No activist contest disclosed.

About Astrana Health Inc
Market cap
$2.1B
1Y TSR
+50.0%
Board grade
C
Sector
Healthcare
CEO
Brandon Sim
Last annual meeting: Jun 10, 2026 · View full Astrana Health Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

 

 

Filed by the Registrant x

 

Filed by a Party other than the Registrant ¨

 

Check the appropriate box:

 

¨Preliminary Proxy Statement
¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨Definitive Proxy Statement
xDefinitive Additional Materials
¨Soliciting Material Pursuant to §240.14a-12

 

Astrana Health, Inc.

(Name of Registrant as Specified in Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

x No fee required.
¨ Fee paid previously with preliminary materials.
¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

 

 

GRAPHIC

Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V91558-P50559 Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. ASTRANA HEALTH, INC. 1668 S. GARFIELD AVENUE 2ND FLOOR ALHAMBRA, CA 91801 ASTRANA HEALTH, INC. 2026 Annual Meeting Vote by June 9, 2026 11:59 PM ET Vote in Person at the Meeting* June 10, 2026 10:00 AM PT 1668 S. Garfield Avenue 3rd Floor Conference Room Alhambra, CA 91801 You invested in ASTRANA HEALTH, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 10, 2026. Get informed before you vote View the Notice of Annual Meeting, Proxy Statement, and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 27, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

GRAPHIC

THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V91559-P50559 Voting Items Board Recommends 1. To elect nine directors to the Board of Directors, each to hold office until the 2027 annual meeting of stockholders of the Company. For Nominees: 01) Kenneth Sim, M.D. 02) Thomas S. Lam, M.D., M.P.H. 03) John Chiang 04) Weili Dai 05) Linda Dong 06) J. Lorraine Estradas, R.N., B.S.N., M.P.H. 07) Mitchell W. Kitayama 08) Matthew Mazdyasni 09) David G. Schmidt 2. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. To approve, on a non-binding advisory basis, the compensation program for the Company’s named executive officers as disclosed in the Company’s proxy statement. For 4. To approve the Astrana Health, Inc. Amended and Restated 2024 Equity Incentive Plan. For NOTE: In their discretion, the proxies are authorized to vote on any such other business that may properly be presented before the annual meeting or at any adjournment or postponement thereof.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Astrana Health Inc (ASTH)

Reference

Frequently asked questions

When did Astrana Health Inc file this DEFA14A?
Astrana Health Inc (ASTH) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 17, 2026. The accession number assigned by EDGAR is 0001104659-26-044544.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Astrana Health's board recommends voting for all four proposals at the 2026 annual meeting. No activist contest disclosed. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Astrana Health Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Astrana Health Inc has filed under CIK 1083446, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer